3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
CNS
1
Conditions
Brain Neoplasms
15
Glioblastoma
9
Carcinoma, Non-Small-Cell Lung
9
Gliosarcoma
7
Central Nervous System Neoplasms
4
Lung Neoplasms
3
Oligodendroglioma
2
Neuroblastoma
2
Neoplasms
2
Glioma
2
Astrocytoma
2
Untreated Childhood Anaplastic Astrocytoma
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Meningioma
1
Glioma, Subependymal
1
Esthesioneuroblastoma, Olfactory
1
Carcinoma, Medullary
1
Adenocarcinoma, Follicular
1
Interventions
selpercatinib
2
alectinib
1
Pemetrexed
1
Gefitinib
1
Erlotinib Hydrochloride
1
Carboplatin
1
AZD3759
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Gefitinib
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled